Max Lataillade

2.0k total citations
50 papers, 1.3k citations indexed

About

Max Lataillade is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Max Lataillade has authored 50 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Infectious Diseases, 42 papers in Virology and 9 papers in Emergency Medicine. Recurrent topics in Max Lataillade's work include HIV/AIDS drug development and treatment (48 papers), HIV Research and Treatment (42 papers) and HIV/AIDS Research and Interventions (32 papers). Max Lataillade is often cited by papers focused on HIV/AIDS drug development and treatment (48 papers), HIV Research and Treatment (42 papers) and HIV/AIDS Research and Interventions (32 papers). Max Lataillade collaborates with scholars based in United States, United Kingdom and Peru. Max Lataillade's co-authors include Michael J. Kozal, Jennifer Chiarella, Mark Krystal, George J. Hanna, Rong Yang, Jean‐Michel Molina, Donnie McGrath, Victoria Wirtz, Samit R. Joshi and Neelanjana Ray and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Max Lataillade

48 papers receiving 1.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Max Lataillade 1.2k 1.0k 181 165 144 50 1.3k
Annemarie M. J. Wensing 1.6k 1.3× 1.4k 1.4× 214 1.2× 333 2.0× 87 0.6× 23 1.8k
Cindy Vavro 1.4k 1.2× 1.1k 1.1× 173 1.0× 284 1.7× 308 2.1× 26 1.5k
Johan Vingerhoets 2.4k 2.1× 2.1k 2.0× 318 1.8× 556 3.4× 176 1.2× 46 2.6k
Winai Ratanasuwan 808 0.7× 594 0.6× 120 0.7× 257 1.6× 144 1.0× 38 957
Scott Brun 1.2k 1.0× 933 0.9× 47 0.3× 122 0.7× 346 2.4× 20 1.4k
Jorge Santana 690 0.6× 571 0.5× 123 0.7× 152 0.9× 111 0.8× 16 950
Ben Van Baelen 622 0.5× 296 0.3× 83 0.5× 373 2.3× 37 0.3× 13 826
Nicolas Margot 2.7k 2.3× 2.5k 2.4× 413 2.3× 488 3.0× 193 1.3× 73 2.9k
Maria Cecília Araripe Sucupira 654 0.6× 646 0.6× 118 0.7× 252 1.5× 45 0.3× 59 966
Jan Fourie 882 0.8× 678 0.7× 42 0.2× 149 0.9× 190 1.3× 13 939

Countries citing papers authored by Max Lataillade

Since Specialization
Citations

This map shows the geographic impact of Max Lataillade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Lataillade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Lataillade more than expected).

Fields of papers citing papers by Max Lataillade

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Lataillade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Lataillade. The network helps show where Max Lataillade may publish in the future.

Co-authorship network of co-authors of Max Lataillade

This figure shows the co-authorship network connecting the top 25 collaborators of Max Lataillade. A scholar is included among the top collaborators of Max Lataillade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Lataillade. Max Lataillade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Aberg, Judith A., Christine Katlama, Shannon Schrader, et al.. (2023). Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1. Infectious Diseases and Therapy. 12(9). 2321–2335. 7 indexed citations
3.
Zhang, Ying, et al.. (2023). Open‐label, drug–drug interaction study between the HIV‐1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. British Journal of Clinical Pharmacology. 89(7). 2236–2245. 1 indexed citations
4.
Anderson, Sarah‐Jane, Miranda Murray, David Cella, et al.. (2021). Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals. Patient. 15(1). 131–143. 2 indexed citations
5.
Zhang, Sharon, Neelanjana Ray, Brett R. Beno, et al.. (2019). Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. PLoS ONE. 14(10). e0224076–e0224076. 14 indexed citations
6.
7.
Lin, Zeyu, Joseph L. Cantone, Hao Lu, et al.. (2016). Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors. PLoS Pathogens. 12(11). e1005990–e1005990. 16 indexed citations
8.
Pavía-Ruz, Noris, Xavier Sáez‐Llorens, Torsak Bunupuradah, et al.. (2015). Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age. The Pediatric Infectious Disease Journal. 34(12). 1355–1360. 4 indexed citations
9.
Lalezari, Jacob, Gulam Latiff, Cynthia Brinson, et al.. (2015). Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. The Lancet HIV. 2(10). e427–e437. 50 indexed citations
10.
Gupta, Samir K., Grace A. McComsey, Juan Echevarría, et al.. (2015). Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. The Lancet HIV. 3(1). e13–e22. 9 indexed citations
11.
Lalezari, Jacob, Gulam Latiff, Cynthia Brinson, et al.. (2014). Safety profile of HIV‐1 attachment inhibitor prodrug BMS‐663068 in antiretroviral‐experienced subjects: week 24 analysis. Journal of the International AIDS Society. 17(4S3). 19530–19530. 4 indexed citations
12.
Brinson, Cynthia, Jacob Lalezari, Melanie Thompson, et al.. (2014). HIV‐1 attachment inhibitor prodrug BMS‐663068 in antiretroviral‐experienced subjects: week 24 sub‐group analysis. Journal of the International AIDS Society. 17(4S3). 19529–19529. 2 indexed citations
13.
Zhou, Nannan, Beata Nowicka-Sans, Brian McAuliffe, et al.. (2013). Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. Journal of Antimicrobial Chemotherapy. 69(3). 573–581. 55 indexed citations
14.
Ray, Neelanjana, Carey Hwang, Matthew D. Healy, et al.. (2013). Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068. JAIDS Journal of Acquired Immune Deficiency Syndromes. 64(1). 7–15. 39 indexed citations
15.
Lataillade, Max, Jennifer Chiarella, Rong Yang, et al.. (2012). Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing. PLoS ONE. 7(2). e30118–e30118. 31 indexed citations
16.
Kozal, Michael J., Sergio Lupo, Edwin DeJesus, et al.. (2012). A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results. HIV Clinical Trials. 13(3). 119–130. 70 indexed citations
17.
Lataillade, Max, Jennifer Chiarella, Rong Yang, et al.. (2010). Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study. PLoS ONE. 5(6). e10952–e10952. 101 indexed citations
18.
Molina, Jean‐Michel, Jaime Andrade‐Villanueva, Juan Echevarría, et al.. (2010). Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 53(3). 323–332. 183 indexed citations
19.
Lataillade, Max & Michael J. Kozal. (2006). The Hunt for HIV-1 Integrase Inhibitors. AIDS Patient Care and STDs. 20(7). 489–501. 44 indexed citations
20.
Maslow, Joel N., et al.. (2005). Concurrent Outbreak of Multidrug-Resistant and Susceptible Subclones of Acinetobacter baumannii Affecting Different Wards of a Single Hospital. Infection Control and Hospital Epidemiology. 26(1). 69–75. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annemarie M. J. Wensing Breakdown of academic impact, for papers by Cindy Vavro Breakdown of academic impact, for papers by Johan Vingerhoets Breakdown of academic impact, for papers by Winai Ratanasuwan Breakdown of academic impact, for papers by Scott Brun Breakdown of academic impact, for papers by Jorge Santana Breakdown of academic impact, for papers by Ben Van Baelen Breakdown of academic impact, for papers by Nicolas Margot Breakdown of academic impact, for papers by Maria Cecília Araripe Sucupira Breakdown of academic impact, for papers by Jan Fourie
Rankless by CCL
2026